hotspot -WSS

hotspot

author：hotspot 2025-09-29 22:50:20 - browse：584

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

WSS

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Arena BioWorks launches in Cambridge to speed drug discovery

JPM pitch from hospitals? Revenue streams outside of patient care

What STAT readers think about the FDA and patient advocacy

Why health records don't always know when patients are dead

Wikipedia

hotspot

Gilead needs Arcellx more than ever

leisure time

Cancer drug shortages should be causing more outrage

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Medicare details structure of new drug price negotiation program

What STAT readers think about the FDA and patient advocacy

Continuity nursing helped my family in our darkest PICU moments

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Apple is now the first public company to be valued at $3 trillion

Medicare Advantage overpayments discussion gets experts fired up

Supreme Court strikes down use of affirmative action

Carvykti CAR

focus

What STAT readers think about the FDA and patient advocacy

Medicare Advantage overpayments discussion gets experts fired up

Gene therapy denied for Afghan refugee whose father aided U.S.

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Virtual care provider acquires bankrupt Pear's prescription apps

SNAP should offer more nutrition education

focus

focus

Wikipedia

hotspot